Chronic lymphocytic leukemia in Brazil: A retrospective analysis of 1903 cases

Real-world analysis of treatment patterns and clinical outcomes in patients with newly diagnosed chronic lymphocytic leukemia from seven Latin American countries

“…However, in a US registry of academic, community and government centers, chlorambucil based therapy (either in combination with immunotherapy or monotherapy) made up only 5.7% for first line treatment regimens [6]. Our findings are consistent with the results of a Brazilian CLL registry which included 1903 patients enrolled from 2004 to 2016 and reported that 65% of patients received chlorambucil at any point during their treatment, followed by fludarabine-based regimens (41%), rituximab in combination with other drug(s)(22%), and CHOP/CVP-like regimens (19%) [7]. Also, our results underscore the low utilization of novel therapies in the region such as biofunctional alkylating agents (e.g.…”

High frequency of chronic lymphocytic leukemia-like low-count monoclonal B-cell lymphocytosis in Japanese descendants living in Brazil

“…Despite this, preliminary data suggest that prevalence of CLL in Japanese living in Brazil is also lower than in other ethnic groups living in the same region. Thus, based on the Brazilian CLL registry data, only 0.42% Japanese patients have been included among all CLL cases registered in the State of Sao Paulo, 13 a region where 690,600 Japanese descendants live among an overall (age-matched) population of 45,230,000 individuals (1.5% of the population living in Sao Paulo), further supporting an ethnical/genetic background, more than an environment-related trigger in determining the lower prevalence of CLL in Japan 2 versus Europe and North-America. However, in a recent study in Taiwan, a lower prevalence of MBL of 1.3% (4 of 302) has been reported.…”

Lower access to risk stratification tests and drugs, and worse survival of chronic lymphocytic leukaemia patients treated in public as compared to private hospitals in Brazil: A retrospective analysis of the Brazilian registry of chronic lymphocytic leukaemia

“…Overall, the Brazilian Registry of CLL appears to be representative of the Brazilian CLL population. As previously observed in a preliminary analysis of the registry [ 13 ], the median age of patients enrolled in the Brazilian Registry of CLL was 65 years, whereas the median age of patients at diagnosis was reported in the Surveillance, Epidemiology, and End Results (SEER) Program was 71 years ( https://seer.cancer.gov/csr/1975_2007 ), which could be explained by a significant gap between life expectancy in Brazil (75.9) and the United States (78.5) (World Health Statistics: Monitoring health for the SDGs. https://www.who.int/data/gho/data/indicators/indicator‐details/GHO/ ) [ 14 ].…”

“…Overall, the Brazilian Registry of CLL appears to be representative of the Brazilian CLL population. As previously observed in a preliminary analysis of the registry [13], the median age of patients enrolled in the Brazilian Registry of CLL was 65 years, whereas the median age of patients at diagnosis was reported in the Surveillance, Epidemiology, and End Results (SEER) Program was 71 years ( https://seer.cancer.…”